Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Busine...(ternative pathway which Taligen's founde...),Health

Date:12/1/2008

ternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process. Taligen's headquarters and late-stage research and development operations are located in Cambridge, Mass. The company also maintains a drug discovery operation in Denver under Michael Holers, M.D., which closely collaborates with an international complement biology research community. For more information, visit HYPERLINK "http://www.taligentherapeutics.com/"www.taligentherapeutics.com.

This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to development of the Company's product candidates and potential advantages of the Company's technology and product candidates. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in this release.

    Media Contacts:

    Robert Flamm, Ph.D. or David Schull
    Russo Partners
    (212) 845-4226
    robert.flamm@russopartnersllc.com
    david.schull@russopartnersllc.com

'/>"/>

SOURCE Taligen Therapeutics Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Precision Therapeutics Secures $43 Million in Venture Capital Funding
2. Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results
3. Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
4. Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
5. Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product
6. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
7. Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
8. Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
9. Cornerstone Therapeutics Announces New Board of Directors
10. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
11. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics